Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone versus two-food elimination diet for adult eosinophilic esophagitis
ACTRN12619000141145Phase 3Not yet recruiting
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluticasone in eosinophilic esophagitis (EoE) (2 arms), sponsored by Royal Brisbane and Women's Hospital. Primary endpoint: Histological remission. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
fluticasone
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on ACTRN12619000141145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000141145.